Bacterial pneumonia primary prevention

Revision as of 05:58, 2 March 2022 by AroojNaz (talk | contribs)
Jump to navigation Jump to search

Pneumonia Main Page

Bacterial pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bacterial pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bacterial pneumonia primary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bacterial pneumonia primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bacterial pneumonia primary prevention

CDC onBacterial pneumonia primary prevention

Bacterial pneumonia primary prevention in the news

Blogs on Bacterial pneumonia primary prevention

to Hospitals Treating Bacterial pneumonia

Risk calculators and risk factors for Bacterial pneumonia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz

Overview

The goal of Primary prevention is to prevent the occurrence of an illness or a disease before it ever occurs. In the case of bacterial pneumonia, primary prevention can be achieved by the administration of vaccination as well as attempting to control underlying comorbidities that may predispose an individual to pneumonia. Pneumococcus Vaccines include the PCV13 (Conjugate vaccine) and the PPSV23 (Polysaccharide vaccine). The PCV13 vaccine is indicated in infants and childhood routine vaccines (children younger than 2 years) as well as all adults aged 65 years or older whereas the PPSV23 vaccine is recommended for all adults over the age of 65 as well as adults aged 19-64 with certain medical conditions including chronic heart, lung, or liver diseases, diabetes, smokers and alcoholics. The killed intramuscular influenza vaccine should be given annually. Strict blood glucose and blood pressure control can help in preventing disease prevalence. When certain conditions are present, such as in children that have asplenia, it may also be helpful to treat with prophylactic antibiotics.[1] Educating the public as well as identifying those most susceptible to infection can help reduce the risk of pneumonia.

Vaccinations

- Routinely administered vaccines include:

  • Pneumococcus (Intramuscular Conjugate or polysaccharide vaccine)
  • Annual vaccine against H. influenza (Intramuscular killed vaccine)
Pneumococcus Vaccines[2][3]
Advantages Disadvanatges Indications
PCV13 (Conjugate vaccine)
  • Immune response is more effective, especially in the elderly and children under the age of 2
  • Long-lasting immunity due to the formation of memory B cells
  • Mucosal immunity (promotes herd immunity)
PPSV23 (Polysaccharide vaccine)
  • Protects against a wider range of serotypes
  • Antibodies decline over 5 years
  • Does not produce an immunological response in children under the age of 2
  • Recommended for all adults over the age of 65
  • Recommended for ages 19-64 with certain medical conditions:
  1. Chronic heart, lung, or liver diseases
  2. Diabetics
  3. Current smokers
  4. Alcoholics
PCV13 + PPSV23
  • All patients above the age of 65
  • Very high-risk patients below the age of 65
  1. Sickle cell disease and asplenia
  2. Immunocompromised patient
  3. Chronic kidney disease
  4. CSF fluid leaks


Controlling Underlying Comorbidities and Patient Education

Conditions Requiring Prophylaxis

For children that have asplenia (including functional asplenia, as seen in sickle-cell disease), daily antimicrobial prophylaxis with oral penicillin V in addition to immunization is recommended. For patients with a history of splenectomy, antibiotics should be continued for a period of 1 year after the surgery.[1]

References

  1. 1.0 1.1 https://www.cdc.gov/pneumococcal/clinicians/prevention.html. Missing or empty |title= (help)
  2. Hayward S, Thompson LA, McEachern A (2016). "Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ". J Patient Cent Res Rev. 3 (2): 111–115. doi:10.17294/2330-0698.1214. PMC 4927079. PMID 27376105.
  3. Grief SN, Loza JK (2018). "Guidelines for the Evaluation and Treatment of Pneumonia". Prim Care. 45 (3): 485–503. doi:10.1016/j.pop.2018.04.001. PMC 7112285 Check |pmc= value (help). PMID 30115336.
  4. "StatPearls". 2022. PMID 30020693.


Template:WikiDoc Sources